Paradoxical expression of AHCYL1 affecting ovarian carcinogenesis between chickens and women

Experimental Biology and Medicine

Volumn 237, Issue 7, 2012, Pages 758-767

  Jeong, Wooyoung ^a   Kim, Hee Seung ^b   Kim, Yong Beom ^c   Kim, Min A ^b   Lim, Whasun ^a   Kim, Jinyoung ^a   Jang, Hyun Jun ^a   Suh, Dong Hoon ^b   Kim, Kidong ^c   Chung, Hyun Hoon ^b   Bazer, Fuller W ^a,d   Song, Yong Sang ^a,b   Han, Jae Yong ^a   Song, Gwonhwa ^a  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

AHCYL1; Cancer; Ovary; Prognostic factor

Indexed keywords

ADENOSYLHOMOCYSTEINASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA CELL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; METHYLATION; NONHUMAN; OVARY CANCER; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

ADENOSYLHOMOCYSTEINASE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHICKENS; CPG ISLANDS; DATA INTERPRETATION, STATISTICAL; DNA METHYLATION; FEMALE; HUMANS; MICROSCOPY, FLUORESCENCE; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84865314338     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2012.011433     Document Type: Article

References (43)

1. Suh DH, Kim JW, Kim K, Kang SB. Major clinical research advances in gynecologic cancer in 2010. J Gynecol Oncol 2010;21:209-18.
2. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S. Carcinoma of the ovary. Int J Gynaecol Obstet 2003;83(Suppl. 1):135-66.
3. th Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95(Suppl. 1):S161-92.
4. Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer 2011;47(Suppl. 3):S116-30.
5. Dutta S, Wang FQ, Phalen A, Fishman DA. Biomarkers for ovarian cancer detection and therapy. Cancer Biol Ther 2010;9:668-77.
6. Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J, Luborsky JL. Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer. Int J Gynecol Cancer 2009;19:531-9.
7. Vanderhyden BC, Shaw TJ, Ethier JF. Animal models of ovarian cancer. Reprod Biol Endocrinol 2003;1:67.
8. Stammer K, Edassery SL, Barua A, Bitterman P, Bahr JM, Hales DB, Luborsky JL. Selenium-binding protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer. Gynecol Oncol 2008;109:115-21.
9. Dekker JW, Budhia S, Angel NZ, Cooper BJ, Clark GJ, Hart DN, Kato M. Identification of an S-adenosylhomocysteine hydrolase-like transcript induced during dendritic cell differentiation. Immunogenetics 2002;53:993-1001.
10. Turner MA, Yang X, Yin D, Kuczera K, Borchardt RT, Howell PL. Structure and function of S-adenosylhomocysteine hydrolase. Cell Biochem Biophys 2000;33:101-25.
11. Ando H, Mizutani A, Matsu-ura T, Mikoshiba K. IRBIT, a novel inositol 1,4,5-trisphosphate (IP3) receptor-binding protein, is released from the IP3 receptor upon IP3 binding to the receptor. J Biol Chem 2003;278:10602-12.
12. Ando H, Mizutani A, Kiefer H, Tsuzurugi D, Michikawa T, Mikoshiba K. IRBIT suppresses IP3 receptor activity by competing with IP3 for the common binding site on the IP3 receptor. Mol Cell 2006;22:795-806.
13. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000;1:11-21.
14. Lim W, Kim JH, Ahn SE, Jeong W, Kim J, Park TS, Jang HJ, Lee SI, Bazer FW, Han JY, Song G. Avian SERPINB11 gene: a marker for ovarian cancer in chickens. Exp Biol Med 2012;237:150-9.
15. Song G, Bazer FW, Spencer TE. Pregnancy and interferon tau regulate RSAD2 and IFIH1 expression in the ovine uterus. Reproduction 2007;133:285-95.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
17. Lim W, Kim JH, Ahn SE, Jeong W, Kim J, Bazer FW, Han JY, Song G. Avian SERPINB11 gene: characteristics, tissue-specific expression, and regulation of expression by estrogen. Biol Reprod 2011;85:1260-8.
18. Shepherd TG, Theriault BL, Campbell EJ, Nachtigal MW. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 2006;1:2643-9.
19. Giles JR, Olson LM, Johnson PA. Characterization of ovarian surface epithelial cells from the hen: a unique model for ovarian cancer. Exp Biol Med (Maywood) 2006;231:1718-25.
20. Kim HS, Park NH, Kang S, Seo SS, Chung HH, Kim JW, Song YS, Kang SB. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. J Obstet Gynaecol Res 2010;36:86-93.
21. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Manci N, Scambia G, Dell'Anna T, Fossati R, Floriani I, Rossi RS, Grassi R, Favalli G, Raspagliesi F, Giannarelli D, Martella L, Mangioni C. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97:560-6.
22. Song G, Spencer TE, Bazer FW. Progesterone and interferon-tau regulate cystatin C in the endometrium. Endocrinology 2006;147:3478-83.
23. Ahn SE, Choi JW, Rengaraj D, Seo HW, Lim W, Han JY, Song G. Increased expression of cysteine cathepsins in ovarian tissue from chickens with ovarian cancer. Reprod Biol Endocrinol 2010;8:100.
24. Zhuge Y, Lagman JA, Ansenberger K, Mahon CJ, Daikoku T, Dey SK, Bahr JM, Hales DB. CYP1B1 expression in ovarian cancer in the laying hen Gallusdomesticus. Gynecol Oncol 2009;112:171-8.
25. Ansenberger K, Zhuge Y, Lagman JA, Richards C, Barua A, Bahr JM, Hales DB. E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer. Gynecol Oncol 2009;113:362-9.
26. Hales DB, Zhuge Y, Lagman JA, Ansenberger K, Mahon C, Barua A, Luborsky JL, Bahr JM. Cyclooxygenases expression and distribution in the normal ovary and their role in ovarian cancer in the domestic hen (Gallus domesticus). Endocrine 2008;33:235-44.
27. Urick ME, Johnson PA. Cyclooxygenase 1 and 2 mRNA and protein expression in the Gallus domesticus model of ovarian cancer. Gynecol Oncol 2006;103:673-8.
28. Giles JR, Shivaprasad HL, Johnson PA. Ovarian tumor expression of an oviductal protein in the hen: a model for human serous ovarian adenocarcinoma. Gynecol Oncol 2004;95:530-3.
29. Murdoch WJ, Van Kirk EA, Alexander BM. DNA damages in ovarian surface epithelial cells of ovulatory hens. Exp Biol Med (Maywood) 2005;230:429-33.
30. Jackson E, Anderson K, Ashwell C, Petitte J, Mozdziak PE. CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. Gynecol Oncol 2007;104:192-8.
31. Rodriguez-Burford C, Barnes MN, Berry W, Partridge EE, Grizzle WE. Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention. Gynecol Oncol 2001;81:373-9.
32. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O'Briant K, Drescher C, Urban N. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:26-38.
33. Johnson KA. The standard of perfection: thoughts about the laying hen model of ovarian cancer. Cancer Prev Res (Phila) 2009;2:97-9.
34. Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, Berchuck A, Kopelovich L, Rodriguez GC. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila) 2009;2:114-21.
35. Kim HS, Lim W, Kim YB, Kim MA, Park YS, Park NH, Bazer FW, Song YS, Han JY, Song G. SERPINB3 in the chicken model of ovarian cancer: a novel biomarker for predicting platinum resistance and survival in patients with epithelial ovarian cancer. The 97th Annual Congress of Korean Society of Obstetrics and Gynecology. Seoul, Republic of Korea, 2011.
36. Wittig R, Nessling M, Will RD, Mollenhauer J, Salowsky R, Munstermann E, Schick M, Helmbach H, Gschwendt B, Korn B, Kioschis P, Lichter P, Schadendorf D, Poustka A. Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res 2002;62:6698-705.
37. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006;5:483-93.
38. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
39. Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci USA 1995;92:6414-8.
40. Sjolund J, Johansson M, Manna S, Norin C, Pietras A, Beckman S, Nilsson E, Ljungberg B, Axelson H. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 2008;118:217-28.
41. Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist 2007; 12:535-42.
42. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 2006;281:39819-30.
43. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010;24:1580-9.